RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Anti-TNF Therapy and CV Risk in RA
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 9
SP 12
OP 13
DO 10.1177/155989771209009
UL http://mdc.sagepub.com/content/12/9/12.abstract
AB Systemic inflammation in patients with rheumatoid arthritis (RA) leads to a greater risk of cardiovascular (CV) events that are linked to tumor necrosis factor (TNF)-related atherogenesis. Anti-TNF therapies have been shown in observational studies to reduce the risk of CV events in patients with RA. The objective of this retrospective medical record review was to compare the effect of exposure to anti-TNF treatment on the risk of CV events in patients with RA with those who were treated with methotrexate and other disease-modifying therapies.